Peptide library / Digestive & weight / Maridebart cafraglutide
Maridebart cafraglutide
An investigational monthly injection that pairs a GLP-1 agonist with an antibody that blocks the GIP receptor.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesityLarge trials
- Type 2 diabetes controlSmall human studies
How it is thought to work
Unlike tirzepatide, which activates GIP, MariTide blocks the GIP receptor while activating GLP-1, in a single molecule that lasts long enough for monthly or less frequent dosing.
What the evidence shows
A phase 2 trial in adults with obesity reported average weight loss of up to about 20 percent at 52 weeks without a clear plateau. Amgen has started a phase 3 program called MARITIME.
Safety and unknowns
Nausea and vomiting were frequent, especially at the start of treatment, and were reduced with dose escalation.
Regulatory status
Not approved. Phase 3 is under way.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Mazdutide
In clinical trialsA dual GLP-1 and glucagon receptor agonist developed by Innovent, approved in China for obesity.
Oxyntomodulin
Wellness and performanceA natural gut hormone that activates both GLP-1 and glucagon receptors, and inspired later dual agonists.
Lutetium Lu-177 dotatate
FDA-approvedA radioactive peptide that delivers radiation directly to neuroendocrine tumors.
General information, not medical advice. Do not buy or inject unregulated peptides.